Scientific Advisory Board

Jeff Alder, Ph.D.

Jeff Alder has 30 years experience in infectious disease research and clinical development at both big Pharmaceutical companies (Abbott, Bayer) and Biotech (Cubist Pharmaceuticals). He has been involved with multiple drug approval filings (both NDA and sNDA) to the Food and Drug Administration, European Medicines Agency, as well as in China  and Japan. Jeff was a leading Presenter at 3 FDA Advisory Committee meetings for the approval of new drugs (daptomycin) and review of prior drug safety and efficacy (ciprofloxacin, moxifloxacin), and had the lead role in final label negotiations with the FDA and EMA for several anti-bacterial products. He is a frequent presenter at FDA, EMA, cFDA, and PMDA for clinical trial design and analysis, and a presenter and panelist at FDA workshops, conferences, and clinical grand rounds for various anti-infective development issues. Jeff is an active NIH/NIAID grant and program reviewer for infectious diseases and has served as chairperson for multiple reviews. He served as chairperson of the Antimicrobial Chemotherapy Division, American Society for Microbiology, 2011 to 2014.

Dr. Alder received his B.S and PhD degree in Microbiology from The Ohio State University and completed his post doctoral training in Medical Microbiology at The University of Wisconsin.

Eric Rowinsky, M.D.

Dr. Rowinsky is an independent consultant and/or board member of various public and private companies and not-for-profit efforts. Dr. Rowinsky has served as an Executive Director and President at Rgenix Inc. and as the Chief Scientific Officer of Clearpath Development Co. From 2005 to 2015, Dr. Rowinsky held various positions with various biotechnology companies. At ImClone Systems (now a wholly-owned subsidiary of Eli Lilly), Dr. Rowinsky and his team developed and registered cetuximab (Erbitux) and ramucirumab in five indications and two other monoclonal antibodies in North America and elsewhere. Dr. Rowinsky has been an Adjuvant Professor of Medicine at New York University School of Medicine since 2005. From 1987 to 2005, Dr. Rowinsky held various academic and research positions with various universities and research institutions including the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio, and the Johns Hopkins University School of Medicine. Dr. Rowinsky is on the board of directors of several public companies including Biogen (NASDAQ: BIIB), Fortress Biotech (NASDAQ: FBIO), Biophytis (EPA: ALBPS), and Verastem (NASDAQ: VSTM). 

Dr. Rowinsky received his B.A. degree from New York University and his M.D. from the Vanderbilt University School of Medicine and completed fellowship training at the Johns Hopkins University School of Medicine.

 Copyright Everest Medicines 2020  云顶药业(苏州)有限公司 苏ICP备20038571号 |  Terms of Use |  Privacy Policy |  Disclaimers

沪公网安备 31010602006477号